Kummeth Charles R. Form 4 BIO-TECHNE / Charles R. Kummeth ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kummeth Charles R.

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								100	I	By Step-Son
Common Stock								100	I	By Step-Daughter
Common Stock	01/28/2022		M		938	A	$106.59	197,539(1)	D
Common Stock	01/28/2022		M		799	A	$125.05	198,338(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$108.49							(2)	08/07/2022	Common Stock	100,450		100,450	D
Stock Options (Right to Buy)	$106.59	01/28/2022		M			938	(2)	08/18/2023	Common Stock	938	$0	256,010	D
Stock Options (Right to Buy)	$125.05	01/28/2022		M			799	(2)	08/09/2024	Common Stock	799	$0	194,771	D
Stock Options (Right to Buy)	$177.32							(2)	08/08/2025	Common Stock	90,334		90,334	D
Stock Options (Right to Buy)	$177.32							(3)	08/08/2025	Common Stock	60,222		60,222	D
Restricted Stock Units	(4)							(5)	(5)	Common Stock	16,937		16,937	D
Stock Options (Right to Buy)	$190.41							(5)	08/07/2026	Common Stock	85,725		85,725	D
Stock Options (Right to Buy)	$190.41							(6)	08/07/2026	Common Stock	57,150		57,150	D
Restricted Stock Units	(4)							(7)	(7)	Common Stock	12,879		12,879	D
Stock Options (Right to Buy)	$267.87							(7)	08/05/2027	Common Stock	57,442		57,442	D
Stock Options (Right to Buy)	$267.87							(8)	08/05/2027	Common Stock	38,295		38,295	D
Stock Options (Right to Buy)	$267.87							(9)	08/05/2027	Common Stock	16,650		16,650	D
Stock Options (Right to Buy)	$267.87							(10)	08/05/2027	Common Stock	16,650		16,650	D
Restricted Stock Units	(4)							(11)	(11)	Common Stock	8,016		8,016	D
Stock Options (Right to Buy)	$481.82							(11)	08/06/2028	Common Stock	31,315		31,315	D
Stock Options (Right to Buy)	$481.82							(12)	08/06/2028	Common Stock	20,876		20,876	D

Explanation of Responses:

1. Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024.

2. Fully exercisable.

3. Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.

4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

5. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

6. Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.

7. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

8. Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.

9. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

10. Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.

11. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

12. Options to purchase 5,219 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.

	/s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed.	02/01/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.